Additionally, an improved OS in grade 3 glioma patients was found to be associated with a higher frequency of CD3−/CD56+/CD94+ NK cells and an upregulated expression of the activatory marker CD69 on NK cells. This evidence concerns the gene KLRD1 and central nervous system cancer.